<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697944</url>
  </required_header>
  <id_info>
    <org_study_id>AMBIDEX</org_study_id>
    <secondary_id>EUDRA−CT 2007−004444−71</secondary_id>
    <nct_id>NCT00697944</nct_id>
  </id_info>
  <brief_title>Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients</brief_title>
  <acronym>AMBIDEX</acronym>
  <official_title>Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fovea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fovea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety of Ambisome 10 mg/kg/week in patients as a preemptive treatment in
      intensive care patients with a sepsis and rising candida colonisation.

      Preemptive treatment (i.e., prophylactic treatment with two high doses of Ambisome®
      administered with an interval of one week, in patiens with a high risk of developing a fungal
      infection) should decrease the incidence of actual systemic infections.

      The incidence of such actual fungal infections will be assessed directly and its impact on
      patients' survival and intensive care resourches assessed
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global assessment of severity of adverse events; incidence, severity and consequences of treatment emergent effects</measure>
    <time_frame>28−day observation period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in the intensive care unit; occurrence of a systemic fungal infection</measure>
    <time_frame>28 days after first treatment administration</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sepsis</condition>
  <condition>Candida</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericine in liposome (Ambisome®)</intervention_name>
    <description>2 IV infusions separated by one week 10 mg/kg per injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Supportive mechanical ventilation for more than 48 h

          -  LOD &gt; 5 with with ailing body systems

          -  Candida colonisation of at least one site in addition to the digestive tract

          -  Suspected nosocomial infection with antibiotic treatment

          -  Informed consent

        Exclusion Criteria:

          -  Patients treated with oral or systemic antifungal agents within 15 days prior to
             inclusion

          -  Patients requiring treatment with an antifungal agent or with a documented (proven or
             probable) fungal infection according to the EORTC criteria

          -  Patients with a SAPS score &gt; 65

          -  Patients with neutropenia of that underwent a bone marrow tar organ transplant or with
             cancer chemotherapy

               -  Blood creatinine &gt; 220 µmol/L

          -  Hemodyalysis

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie AZOULAY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Teaching Hospital Saint Louis, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean−François RI DREYFUS, MD PhD</last_name>
    <phone>33-61-282-6780</phone>
    <email>jfdreyfus@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TIMSIT</last_name>
      <email>jftimsit@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <last_update_submitted>June 13, 2008</last_update_submitted>
  <last_update_submitted_qc>June 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>DREYFUS Medical director</name_title>
    <organization>FOVEA</organization>
  </responsible_party>
  <keyword>FUNGAL INFECTION</keyword>
  <keyword>SEPSIS</keyword>
  <keyword>INTENSIVE CARE</keyword>
  <keyword>AMBISOME</keyword>
  <keyword>PREEMPTIVE TREATMENT</keyword>
  <keyword>Sepsis with candida colonisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

